Clinical Trial Update: Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a regimen of bortezomib, pegylated liposomal doxorubicin (Doxil), and dexamethasone, with or without thalidomide and dexametha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Decadron (Dexamethasone)
• Doxil (liposomal doxorubicin)
• Thalomid (thalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2016-01-22